Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease
- 31 March 2004
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 20 (6) , 931-938
Abstract
SUMMARYBackground: Behavioural and psychological disturbances occur in up to 90% of patients with Alzheimer's disease (AD), have a substantial impact on both patients and caregivers, and are often associated with the decision to institutionalise patients. Galantamine (Reminyl†) is a dual-acting cholinergic treatment that improves cognitive and functional performance, delays the onset of behavioural symptoms and decreases behaviour-associated caregiver distress.Objective: To assess the impact of galantamine on behavioural disturbances and associated caregiver burden in non-institutionalised patients with AD.Methods: This was a 3-month, open-label, multicentre study in Switzerland. Patients with mild-to-moderate AD received galantamine (escalated from 8 to 24 mg/day over 8 weeks). The primary outcome was the Neuropsychiatric Inventory (NPI) for patients who completed 3 months treatment (observed cases, OC). Secondary outcomes included the Nurses’ Observation Scale for Geriatric patients (NOSGER), and the Cl...Keywords
This publication has 25 references indexed in Scilit:
- Unconventional ligands and modulators of nicotinic receptorsJournal of Neurobiology, 2002
- Nicotinic receptors in aging and dementiaJournal of Neurobiology, 2002
- Nicotinic α7 receptors: Synaptic options and downstream signaling in neuronsJournal of Neurobiology, 2002
- Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trialThe Lancet, 2002
- A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home SettingJournal of the American Geriatrics Society, 2001
- Cholinesterase inhibitors: expanding applicationsThe Lancet, 2000
- Local α-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivoNeuroscience, 2000
- A 5-month, randomized, placebo-controlled trial of galantamine in ADNeurology, 2000
- Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medicationNeuroscience, 2000
- Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathologyNeuroscience, 1995